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Sleep disturbances are highly prevalent in women with breast cancer; side effects of cancer treatment
may worsen pre-existing sleep problems and have been pointed to as important determinants of their
incidence. Therefore, we aimed to assess the association between different types of breast cancer
treatment and sleep disturbances, through a systematic review. Medline (using PubMed), CINAHL Plus
with full text, PsycINFO and Cochrane Central Register of Controlled Trials (Central) were searched
from inception to January 2014. Studies that evaluated samples of women with breast cancer, assessed
sleep disturbances with standardized sleep-speciﬁc measures, and provided data for different cancer
treatments were eligible. A total of 12 studies met the inclusion criteria. Three studies evaluated
insomnia, ﬁve studies assessed sleep quality, two provide data on general sleep disturbances and two
analysed speciﬁc sleep parameters. Women submitted to chemotherapy, or radiotherapy, tended to
report higher levels of sleep disturbances. More heterogeneous ﬁndings were observed regarding the
effect of surgical treatment and hormonal therapy. However, a sound assessment of the impact of
these treatments was hampered by differences across studies regarding the outcomes assessed,
reporting bias and the fact that most studies did not control for the effect of potential confounders.
The present review highlights the potential relation between breast cancer treatments and sleep
disturbances, particularly of chemotherapy, though more robust evidence is needed for a proper
understanding of these associations.
© 2014 Elsevier Ltd. All rights reserved.Introduction
In the last decades, the trends towards earlier detection of breast
cancer and use of more effective treatments have resulted in higher
incidence and improved survival, along with lower mortality rates
[1e3]. Currently, breast cancer is one of the most frequent, with an
estimated 1.7 million new cases diagnosed in 2012, corresponding
to 25% of all cancers amongwomen [4]. It is also amajor contributor
to the overall number of disability-adjusted life-years (DALYs) lostologia Clínica, Medicina Pre-
versidade do Porto, Alameda
þ351 225 513 652; fax: þ351due to oncological diseases. In countries with a very high human
development index, the years of life lived with disability account
for over one-third of the age-adjusted DALYs due to breast cancer
[5], which highlights the importance of a comprehensive assess-
ment of its burden.
Sleep disorders are deﬁned as a speciﬁc diagnostic of a wide
range of problems characterized by the symptoms of insomnia,
excessive day sleepiness and/or abnormal movements, behaviours,
or sensations [6]. However, different terms related to sleep disor-
ders have been used in the literature, namely sleep disturbances,
insomnia, impaired sleep, sleep patterns and sleep-wake distur-
bances. Since most of the studies in this topic include the evalua-
tion of sleep disorders, global sleep quality or other sleep
characteristics, sleep disturbances have been previously used to
name all sleep-related outcomes [7].
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estimated that the prevalence of poor sleep in breast cancer pa-
tients range from 20 to 70% [8], depending on the study design and
method of assessment. The proportion of sleep disturbances in this
population is higher than the observed in healthy adults [9,10], and
in other oncological patients [11]. These ﬁndings are particularly
relevant since sleep disturbances have a negative impact on the
physiological and psychological functions, including immune
function [12], cognitive impairment [13], depression [14] and fa-
tigue [15], being likewise a strong predictor of different measures of
quality of life in this population [16].
The aetiology of sleep disturbances in breast cancer patients is
multi-factorial; in fact, demographic, environmental and lifestyle
factors, psychological disturbances and comorbid medical disor-
ders have been pointed to as main factors contributing for its
occurrence [8,17,18]. Cancer-related treatments, and their wide
range of side effects, are other important feature frequently asso-
ciated with the occurrence of sleep disturbances [19,20]. In addi-
tion, breast cancer diagnosis and associated treatments, may also
contribute for worsening pre-existing sleep problems [21].
Therefore, we aimed to assess the relation between different
types of breast cancer treatment and sleep disturbances, through a
systematic review of the published evidence.
Methods
We searched Medline (using PubMed), CINAHL Plus with full
text, PsycINFO and Cochrane Central Register of Controlled Trials
(Central), from inception to January 2014, with the following search
expression: (sleep* OR insomnia OR circadian rhythm OR para-
somnia OR hypersomnia OR awakening OR somnolence OR drows-
iness OR wakefulness) AND breast cancer. Searches in CINAHL Plus
with full text were expanded to also include related words.
Observational and experimental studies addressing the effect of
breast cancer treatments (i.e., surgical treatment, chemotherapy,
radiotherapy and hormonal therapy) on sleep disturbances were
eligible. There were no language restrictions.
The exclusion criteria were the following: 1) studies not
involving humans (in vitro or research conducted in animals); 2)
case reports, qualitative research studies, non-systematic reviews
or reviews not addressing the impact of breast cancer treatments
on sleep disturbances, guidelines, conference or meeting abstracts
and theses; 3) studies not involving women with breast cancer; 4)
studies addressing the role of sleep disturbances as a risk factor for
breast cancer; 5) studies not providing data on sleep disturbances
evaluated with standardized sleep-speciﬁc measures, such as sleep
questionnaires with established psychometric properties of validity
and reliability, sleep diary, actigraphy or polysomnography; 6)
studies not presenting quantitative data on sleep measures for
different breast cancer treatments.
In addition, we excluded all studies that only evaluated circa-
dian phase markers, including melatonin and core body tempera-
ture, as well as cortisol and other endocrine hormones. This is
because there is insufﬁcient evidence to recommend circadian
phase markers for routine clinical evaluation of circadian rhythm
sleep disorders, as some of these biomarkers are strongly affected
by many other factors that may mask the underlying circadian
signals [22e24].
After the identiﬁcation of potentially relevant references of
original studies and the exclusion of multiple reports of the same
article, we performed an initial screening of the reference list
based on their titles and abstracts. Further, we conducted a detail
assessment of the full texts and extracted data from those that
met the selection criteria. The reference lists of the studies
selected for inclusion in the systematic review were also screened,following the same criteria, to identify other potentially eligible
reports.
From each paper selected for the systematic review, we
collected data regarding the country where the study was con-
ducted, the type of study (clinical trial, cohort, caseecontrol, cross-
sectional), sample characteristics (sample size, age, cancer stage,
time since diagnosis), instruments used to assess sleep distur-
bances, estimates of the association between breast cancer treat-
ments and sleep characteristics, or the necessary information to
compute them, and strategies used to control confounding,
whenever applicable. When multiple reports from the same study
were identiﬁed, we extracted data from the report providing the
most detailed and/or valid estimates of the effects of cancer treat-
ments on sleep. Regarding prospective studies with evaluations at
different moments after baseline, only the results corresponding to
the longest follow-up were extracted.
The screening of the reference lists, selection of papers for the
review and data extraction, were accomplished independently by
two researchers (ARC, FF), following predeﬁned criteria. Dis-
crepancies in the assessment performed by the two reviewers
were resolved by consensus or involving a third researcher (NL).
A detailed ﬂowchart of the systematic review is presented as
Fig. 1.
Due to the heterogeneity of the methods used for the
assessment of sleep disturbances, and options for presentation of
results, it was not possible to perform a quantitative synthesis of
the main ﬁndings. Therefore, the impact of different breast cancer
treatments on sleep was analysed taking into account the direc-
tion and statistical signiﬁcance of the associations observed when
comparing each treatment with a reference group (other treat-
ment or absence of that speciﬁc type of treatment). The results
were classiﬁed as “lower levels of sleep disturbances” when the
breast cancer treatments being assessed were negatively associ-
ated with the occurrence of sleep disturbances, or “higher level of
sleep disturbances” when a positive relation was observed.
Additionally, the results were classiﬁed in relation to the corre-
sponding P-values and categorized as follows: <0.050 (statisti-
cally signiﬁcant); 0.050 and <0.100 (close to statistical
signiﬁcance); 0.100 (not statistically signiﬁcant). Whenever
necessary, additional comparisons between treatments were
computed by the authors of the present systematic review, using
the chi-square test for categorical variables, or the t-test for
continuous variables. When the studies evaluated several sleep-
related outcomes, only one result, corresponding to the stron-
gest and/or statistically signiﬁcant relation between treatment
and sleep disturbances, was considered.
Results
Twelve studies were included in the systematic review
[13,16,25e34], which are described in detail in Appendix 1. Most of
these investigations were conducted in North America (10 in the
United States [16,25e28,30e34] and one in Canada [13]) and one
was from Denmark [29]. The reports were published between 1998
and 2013, but mostly since 2011 (58% of the studies). The median
sample size was 101, ranging between 32 and 3002. Nearly all an-
alyses of the effects of cancer treatment on sleep were cross-
sectional, and longitudinal data was retrieved from one study
[27]. The patients' age ranged between 26 and 89 years, and most
studies included only non-metastatic breast cancer patients; only
two reports included metastatic breast cancer patients [27,30]. In
most studies, data were collected after surgery or after completion
of chemotherapy and/or radiotherapy, with the exception of two
cohort studies, one with a baseline assessment prior to surgery and
with monthly assessments for six months following surgery [27],
Fig. 1. Systematic review ﬂowchart.
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Table 1
Assessment of risk of bias or confounding of the studies included in the systematic
review.
Studies included in
the systematic review
Assessment of
sleep disturbances
before treatment
Control of
confoundinga
Absence of
reporting
biasb
Caplette-Gingras, 2013 [13]
Desai, 2013 [25]
Starkweather, 2013 [26]
Van Onselen, 2013 [27]
Bower, 2011 [28]
Colagiuri, 2011 [29]
Rand, 2011 [16]
Palesh, 2008 [30]
Bardwell, 2008 [31]
Fortner, 2002 [32]
Stein, 2000 [33]
Berger, 1998 [34]
Low risk of bias or confounding High risk of bias or confounding.
a Control of confounding was considered absent when studies only provided
crude estimates or data to compute them, regarding the relation between treat-
ments and sleep disturbances.
b Quantitative data regarding the impact of breast cancer treatments on sleep
disturbances is presented only when results are statistically signiﬁcant.
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therapy treatments [34]. Furthermore, the full range of the treat-
ments received by the patients in each of the groups being
compared is not described in most studies.
A summary of the methodological characteristics potentially
associated with bias or confounding is presented in Table 1.
Regarding the timing of assessment of sleep, only one study stated
the evaluation of the participants before surgical treatment [27].
The estimates available from six studies did not control for the
effect of potential confounders [13,25,26,31,32,34]. In four studies,
the impact of breast cancer treatments on sleep disturbances were
not fully reported because the results were not statistically signif-
icant [16,27,32,33].
Concerning the evaluation of sleep disturbances, six different
sleep-speciﬁc instruments were used (Table 2), including ﬁve types
of subjective assessment [mostly based on the Pittsburgh Sleep
Quality Index (PSQI)], and one type of objective measurement of
sleep (wrist actigraphy). Insomnia was evaluated in three studies
included in this systematic review [13,25,31]. Five studies evaluated
sleep quality [16,28,29,32,33], two assessed general sleep distur-
bances [26,27] and two provided data on speciﬁc sleep parameters
[30,34].
The association between breast cancer treatments and sleep
disturbances is summarized in Fig. 2.Surgical treatment
The effect of different surgical treatments on sleep was evalu-
ated in two studies [26,29] (Fig. 2A). Mastectomy and lumpectomy
were associated with lower levels of disturbances when compared
to no surgical treatment (in this case, women were only submitted
to breast biopsy) [26], though not statistically signiﬁcant. Incon-
sistent ﬁndings were observed regarding the effect of mastectomy
when compared with lumpectomy [26,29].Chemotherapy
Overall, a tendency for higher levels of sleep disturbance was
observed in women submitted to chemotherapy [27,28,30,31],
although the opposite was observed in three studies (not statis-
tically signiﬁcant in two) [25,27,29]. When compared with radio-
therapy, chemotherapy was also associated with higher levels of
sleep disturbances [31,33]. Regarding the comparison between
different types of chemotherapy, doxorubicin [34] and FEC
[ﬂuorouracil (5-FU) þ epirubicin þ cyclophosphamide] regimens
may have higher prevalence of sleep disturbances [13]. Women
treated with taxane agents had lower prevalence of sleep distur-
bance than those treated with chemotherapy without taxane
agents [13,25] (Fig. 2B).
Radiotherapy
Breast cancer patients submitted to radiotherapy tended to
report higher levels of sleep disturbances than those not submitted
to this type of treatment [25,29e31]. However, as previously
mentioned, when radiotherapy was compared with chemotherapy,
lower levels of sleep disturbances were observed [31,33] (Fig. 2C).
Hormonal therapy
As shown in Fig. 2D, two studies showed that women submitted
to hormonal therapy were more prone to report sleep disturbances
than those not receiving this type of treatment [29,30]. Although
one study found higher levels of sleep disturbances in women
treated with tamoxifen [31], two other studies reported lower
levels in those women [16,25]. In addition, women taking anas-
trozole presented higher prevalence of insomnia, when compared
with women taking letrozole or exemestane, although these asso-
ciations were not statistically signiﬁcant [25].
Discussion
This systematic review provides an overview of the best avail-
able evidence on the association between different breast cancer
treatments and sleep disturbances.
Despite the inconsistent results, women submitted to chemo-
therapy, as well as radiotherapy, tended to report higher levels of
sleep disturbances. Less consistent results were observed regarding
the impact of surgical treatments and hormonal therapy. However,
the achievement of most robust ﬁndings was hampered by the
heterogeneity of sleep-related outcomes and their assessment, the
partial description of all treatments received by the patients, the
absence of control for confounding observed in most of the studies,
and the presence of reporting bias.
Breast cancer treatments have several associated side effects,
which may contribute to impaired sleep in these patients. The cu-
mulative effect of toxic agents on body functions, the physical
impact of distressing symptoms (including nausea, vomiting,
diarrhoea, urinary frequency or skin reactions related with radio-
therapy), changes in body image and hospitalization, as well as
other comorbid-related conditions (e.g.: pain, fatigue, depression,
anxiety, stress), are frequently reported as the main cause or
aggravating factor for sleep disturbances in this population
[17,18,41]. Another potential risk factor for sleep disturbances
among breast cancer patients is the high proportion of vasomotor
symptomatology, namely hot ﬂashes and night sweats, as a side
effect of chemotherapy-induced ovarian disruption or hormonal
therapy following chemotherapy [42]. Additionally, surgical pro-
cedures are associated with functional impairment, producing pain
and inﬂammatory responses that can impair sleep and anaesthetics
Table 2
Description of the methods used for assessment of sleep disturbances in the studies included in the systematic review.
Studies included in
the systematic review
Methods used for the assessment of sleep disturbances Sleep disturbances included in the analysis
PSQI
[35]
GSDS
[36]
ISI
[37]
WHI-IRS
[38]
Daily Sleep
Diary [39]
Actigraphy
[40]
CapletteeGingras, 2013 [13] ✓ ✓ Insomnia: sleep-onset latency, and/or wake after sleep onset,
of at least 30 min occurred at least 3 times per week
(assessed by daily sleep diary); OR subjective complaints of
sleep difﬁculties, as deﬁned by (a) a score of 3 (much) or 4
(extremely) on the dissatisfaction item of the ISI and
(b) a total ISI score 15.
Desai, 2013 [25] ✓ Insomnia: total ISI score 15.
Starkweather, 2013 [26] ✓ Sleep disturbance: higher total GSDS score.
Van Onselen, 2013 [27] ✓ Sleep disturbance: higher total GSDS score;
Daytime sleepiness: higher GSDS daytime
sleepiness subscale score.
Bower, 2011 [28] ✓ Sleep disturbance: higher PSQI total score.
Colagiuri, 2011 [29] ✓ Sleep difﬁculty: total PSQI score 5.
Rand, 2011 [16] ✓ Sleep disturbance: higher total PSQI score.
Palesh, 2008 [30] ✓ Duration of time in bed: time between entry
into bed and wake-up time;
Sleep latency: latency to sleep onset from entry into bed;
Sleep efﬁciency: ratio of time asleep to time in bed;
Wake after sleep onset: total duration of
wake after sleep onset;
Mean Number of Wake Episodes: mean number of
nocturnal wake episodes;
Average Wake Episode Period: average length of
nocturnal wake episodes.
Bardwell, 2008 [31] ✓ Insomnia: total WHI-IRS score 9.
Fortner, 2002 [32] ✓ Sleep latency: higher PSQI sleep latency subscale score;
Sleep disturbance: higher PSQI sleep disturbance subscale score.
Stein, 2000 [33] ✓ Poor sleep quality: higher PSQI score (modiﬁed version of PSQI).
Berger, 1998 [34] ✓ Mesor: average value of activity movements over a
speciﬁc length of time;
Amplitude: extent of a rhythmic change or range of
activity and rest values over a speciﬁed length of time;
Mesor plus amplitude: overall mean activity and
rhythmic ﬂuctuations over the 24-h period approximately
48 h after treatment;
Awakenings at night: number of awakenings per night.
ISI, insomnia severity index; GSDS, general sleep disturbance scale; PSQI, Pittsburgh sleep quality index; WHI-IRS, women's health initiative e insomnia rating scale.
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riods [43]. Although we could expect higher levels of sleep distur-
bances among women undergoing mastectomy than those
receiving breast conserving surgery, this was not conﬁrmed in our
study.
For a better understanding of the relation between breast cancer
treatment and sleep disturbances, more prospective studies with
baseline evaluations before treatment are needed. In fact, previous
studies have shown that women with breast cancer frequently
report higher levels of sleep disturbances prior to treatment
[15,44,45], whereas for some patients the onset of insomnia fol-
lowed the breast cancer diagnosis and others reported that cancer
either caused or aggravated their sleep difﬁculties [21]. In the only
prospective study included in our systematic review that evaluated
sleep disturbances prior to treatments, it was possible to observe a
slight increase followed by a decrease in sleep disturbances,
although the scores remained above the clinically meaningful cut-
off for sleep disturbances [27]. The trajectory of disruptive symp-
toms during treatments also seems to be particularly inﬂuenced by
pre-treatment symptoms [46].
Despite the increasing interest observed in the last few years
regarding the impact of breast cancer and their treatments on
sleep disturbances, the assessment of these outcomes also needs
to be improved. In fact, several studies were excluded because
they did not evaluate sleep with standardized sleep-speciﬁc
measures. Similar ﬁndings were observed in a previoussystematic review regarding the methodological approaches of
sleep disturbances and quality of life in adults with cancer: of
the 40 studies included only four used a multi-item sleep spe-
ciﬁc instrument [7]. According to the recommendations for a
standard research assessment of sleep or insomnia symptoms, in
epidemiological studies, these characteristics should be evalu-
ated with global sleep and insomnia measures (namely PSQI and
Insomnia Severity Index), sleep diary, actigraphy or poly-
somnography [47]. Thus, we opted to only include those studies
using these types of sleep measures, aiming to guarantee the
quality of sleep assessment. None of the studies included eval-
uated sleep disorders with polysomnography, which is the gold
standard for the assessment of sleep disorders, possibly reﬂect-
ing the costs and efforts that this measure implies. Additionally,
even when different studies used the same instrument, distinct
sleep-related outcomes were provided in the reports; this hin-
dered the comparison of the impact of breast cancer treatments
by type of sleep disturbance.
Although no formal assessment of selection bias could be
accomplished due to the heterogeneity of data presented in each
study, a total of 12 reports were excluded because they did not
present any quantitative estimates regarding the association be-
tween breast cancer treatment and sleep disturbances [48e59].
With the exception of one study that reported that women taking
tamoxifen had poorer sleep quality than those not submitted to this
treatment [58], all of the other studies did not report the direction
Fig. 2. Association between breast cancer treatments and sleep disturbances, namely surgical treatment (A), chemotherapy (B), radiotherapy (C) and hormonal therapy (D).
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analysis underreported results without statistical signiﬁcance,
which may have overestimated our assessment of the impact of
breast cancer treatments on sleep disturbances. Three of the 12
studies included in our review reported data on several sleep-
related outcomes, and we opted to include in the ﬁgures summa-
rizing evidence only those corresponding to the strongest and/or
statistically signiﬁcant relation between treatment and sleep dis-
turbances; although this strategy for data synthesis may also have
contributed to overestimating the relation between treatments and
these side effects, it is more sensitive for the detection of potentially
deleterious effects of treatments.
Another important issue refers to the fact that the associations
between breast cancer treatments and sleep disturbance may be
misestimates due to the lack of control for potential confounding;
in fact, only six of the studies included in the systematic review
presented adjusted estimates. Of the wide range of potential
confounders, for instance, cancer stage, age and menopausal status
appear to be crucial variables. Indeed, treatments options are
dependent of cancer stage and related features (e.g. tumour size)
[60,61], and prevalence of sleep disturbances has been associated
with this factor [21]. Age is also taken into account when deciding
breast cancer treatments [62], and changes in sleep patterns and
higher prevalence of sleep disorders were observed with
increasing age [63]. Additionally, menopausal status may deter-
mine the type of breast cancer treatments, particularly hormonal
therapy [64,65], and postmenopausal women were more likely to
present impaired sleep than pre-menopausal [29,66]. Socio-
economic factors [67,68] and presence of other co-morbidities
[41,62] may also need to be considered in data analysis as po-
tential confounders.This systematic review highlights the need for improvements in
methodological procedures in future studies, particularly the
achievement of a consensual deﬁnition of sleep disturbances, use of
adequate tools for sleep evaluation, longitudinal analysis of sleep
disturbances, with evaluations preformed prior to treatments, as
well as control for the effect of possible confounders. Our results do
not exclude the hypothesis that breast cancer treatments, particu-
larly chemotherapy, are associated with sleep disturbances, but
more robust evidence is needed for a proper understanding of the
effects of treatment regimens on this outcome with potential
impact in the patients' quality of life.Conﬂict of interest statement
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no ethical approval was required.Appendix 1. Detail description of the studies addressing the
association between breast cancer treatments and sleep
disturbances.
1st author,
Year of
publication (REF)
Study description Subjects characteristics Association between breast cancer
treatments and sleep disturbances
Treatment comparison Main results Control of confounding
Caplette-Gingras,
2013 [13]
Country: Canada
Period of data collection:
2005e2007
Type of study:
Cross-sectional
Aim: “To evaluate
the relationship
between insomnia
and objective ( … )
and subjective (… )
measures of
cognitive functioning”
Study population:
Women treated for a
ﬁrst diagnosis of Stage-1
through Stage-3
BCA combining surgery,
CTX, and RT in the
past 4 months and having
received HT for
a minimum of 5 week
Sample size: n ¼ 63
”Insomnia ”: n ¼ 47 vs.
“Good sleepers”: n ¼ 16
Age (yr), Range: 30e60
Cancer stage, n (%): Stage I:
14 (22.2), Stage II: 29
(46.0), Stage III: 20 (31.7)
Treatments, n (%):
CTX regimen: FEC: 3 (4.8),
FEC þ Taxane: 18 (28.6),
AC: 24 (38.1), AC þ
Taxane: 18 (28.6)
FEC vs. ACb
(with or without taxane)
Insomnia: 90.5% vs.
66.7%, p ¼ 0.041a
e
Taxane vs. No taxaneb
(FEC or AC)
Insomnia: 69.4% vs.
81.5%, p ¼ 0.277a
e
Desai,
2013 [25]
Country: USA
Period of data collection:
2008e2009
Type of study: Cross-sectional
Aim: “To understand
the prevalence and risk
factors for insomnia in
postmenopausal
BCA patients receiving AIs”
Study population:
Postmenopausal women
with stage 0eIII BCA
receiving a third
generation AI, who had
completed CTX or RT
at least 1 month
prior to enrolment
Sample size: n ¼ 413
“Clinical insomnia”: n ¼ 77 vs.
“No clinical insomnia”: n ¼ 336
Age (yr), Mean: 61.7,
Range: 33e88
Cancer stage, n (%): Stage I:
167 (40.4), Stage II: 195
(47.2), Stage III: 51 (12.4)
Time since diagnosis, n (%):
<2 yr: 132 (32.0), 2e5
yr: 132 (32.0),
5e10 yr: 102 (24.7), 10
yr: 47 (11.4)
Treatments, n (%):
CTX:None: 158 (38.3), CTX but
no Taxane: 105 (25.4), CTX
including Taxane: 150 (36.3);
RT: 288 (69.7);
Prior Tamoxifen: 140 (33.9),
Current HT: Letrozole: 86 (20.8),
Anastrazole: 278 (67.3),
Exemestane: 49 (11.9)
CTX (with or without
taxane) vs. No CTX
Insomnia: 17.6% vs.
20.3%, p ¼ 0.509a
e
CTX þ taxane vs. CTX
wihout taxane
Insomnia: 17.3% vs.
18.1%, p ¼ 0.875a
e
RT vs. No RT Insomnia: 19.8% vs.
16.0%, p ¼ 0.363
e
Prior tamoxifen vs.
No prior tamoxifen
Insomnia: 17.1% vs.
19.4%, p ¼ 0.575
e
Anastrozole (Arimidex) vs.
Letrozole (Femara)
Insomnia: 20.9% vs.
14.0%, p ¼ 0.155a
e
Anastrozole (Arimidex) vs.
Exemestane (Aromasin)
Insomnia: 20.9% vs.
14.3%, p ¼ 0.287a
e
Letrozole (Femara) vs.
Exemestane (Aromasin)
Insomnia: 14.0% vs.
14.3%, p ¼ 0.957a
e
Starkweather,
2013 [26]
Country: USA
Period of data collection:
2003e2006
Type of study: Cross-sectional
Aim: “To examine the
relationships among pro-
and anti-inﬂammatory
biomarkers and
Age (yr), Mean (SD): 47.7 (7.7),
Range: 27e63
Cancer stage: Stage IeStage III
Time since diagnosis:
Treatments, n (%):
Mastectomy: 21 (65.6),
Lumpectomy: 7 (21.9),
Breast biopsy: 4 (12.5)
Mastectomy vs.
Lumpectomy
Mastectomy vs.
No surgical treatmentc
Lumpectomy vs.
No surgical treatmentc
Sleep disturbance:
Mean (SD): 45.6 (21.1)
vs. 38.1 (10.6), p ¼ 0.38
Sleep disturbance:
Mean (SD): 45.6 (21.1)
vs. 52.8 (16.3), p ¼ 0.527a
Sleep disturbance:
e
e
e
(continued on next page)
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(continued )
1st author,
Year of
publication (REF)
Study description Subjects characteristics Association between breast cancer
treatments and sleep disturbances
Treatment comparison Main results Control of confounding
the presence of pain and
other symptoms
(anxiety, depression, fatigue,
and sleep disorder)
prior to induction of CTX”
Study population: Women
with early-stage BCA at
1 month following ﬁne
needle biopsy or breast
tumour resection (lumpectomy
or mastectomy)
but prior to induction of CTX
Sample size: n¼32
Mean (SD): 38.1 (10.6) vs.
52.8 (16.3), p ¼ 0.100a
Van Onselen,
2013 [27]
Country: USA
Type of study: Cohort
Aim: “To evaluate how
sleep disturbance and
daytime sleepiness
changed from before to
6 months following
surgery and whether certain
characteristics predicted
initial levels and/or the
trajectories of these
parameters“
Study population: Women
who underwent
unilateral BCA surgery
were enrolled prior to
surgery and evaluated
monthly for 6 months
Sample size: n ¼ 396
Age (yr), Mean (SD):
54.9 (11.6)
Cancer stage, n (%):
Stage 0: 73 (18.3),
Stage I:151 (37.9),
Stage IIA, IIB: 141 (35.4),
Stage IIIA, IIIB, IIIC, IV:33 (8.3)
Treatments, n (%):
Breast-conserving: 318 (79.9),
Mastectomy: 80 (20.1), Sentinel
node biopsy: 328 (82.4), Axillary
lymph node dissection: 149 (37.4),
Breast reconstruction at
the time of surgery: 86 (21.6),
Neo-adjuvant CTX: 79 (19.8),
Adjuvant CTX: 133 (33.6),
Adjuvant RT: 224 (56.6)
Neo-adjuvant CTX vs. No neo-adjuvant CTX
Adjuvant CTX vs. No-adjuvant CTX
Daytime sleepiness:
Coefﬁcient (SE) from
Linear Modeld: - 0.178
(0.069), p < 0.05f;
Coefﬁcient (SE) from
Quadratic Modele: 0.019
(0.011), p ¼ NS
Sleep disturbance:
Coefﬁcient (SE) from
Linear Modeld: 3.277
(0.874), p < 0.001f;
Coefﬁcient (SE) from
Quadratic Modele:
0.421 (0.144), p < 0.010
Daytime sleepiness
Coefﬁcient(SE) from
Linear Modeld: 0.266
(0.056), p < 0.001;
Coefﬁcient (SE) from
Quadratic Modele:
0.036 (0.009), p < 0.001
Hierarchical linear models
adjusted for education,
employment status, fear
of future diagnostic test,
and adjuvant CTX
Hierarchical linear
models adjusted for
education and depression
symptoms
Hierarchical linear
models adjusted for
education, employment
status, fear of future diagnostic
test, and neo-adjuvant CTX
Bower,
2011 [28]
Country: USA
Type of study: Cross-sectional
Aim: “To characterize
the prevalence and
comorbidity of fatigue,
depressive symptoms,
and sleep disturbance (…);
to determine the contribution of
treatment-related factors to
behavioural symptoms
and inﬂammation (…)
and to test the hypothesis
that inﬂammatory
processes would contribute
to these symptoms”
Study population: Women
who completed
Age (yr), Mean: 51.2, Range: 32e66
Cancer stage: Stage 0 e Stage IIIA
Time since diagnosis (months),
Mean: 6.7, Range: 1.7e12.5
Treatments, n (%):
No CTX (n ¼ 53, 51.5%) 
Surgery only: 14 (13.6),
Surgery þ RT: 39 (37.9);
CTX (n ¼ 50, 48.5%) 
Surgery þ CTX: 9 (8.7),
Surgery þ RT þ
CTX: 41 (39.8)
CTX vs. No CTX Sleep disturbance:
Mean (SD): 8.98 (3.62)
vs. 7.19 (4.02), p ¼ 0.01
P-values from analysis of
covariance controlling for age,
time since treatment
completion, and RT
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primary cancer treatment
(surgery, RT, and/or CTX)
within the past 3 months
and not yet started ET
Sample size: n ¼ 103
Colagiuri,
2011 [29]
Country: DNK
Period of data collection:
2001e2004
Type of study:
Cross-sectional analysis
Aim: To investigate “the
prevalence and
predictors of clinically
signiﬁcant sleep
difﬁculty in women
with primary BCA”
Study population:
Women included in
a nationwide cohort of
Danish women treated
for primary BCA completed
questionnaires three to
four months post-surgery
Sample size: n ¼ 3002
“No Sleep Difﬁculty”
(PSQI5):n ¼ 1264
vs. “Sleep Difﬁculty”
(PSQI5): n ¼ 1738
Age (yr), Mean: 54.4, Range: 26e70
Tumour grade, n (%): 1: 720 (23.8),
2: 1094 (36.2), 3: 636 (21.1),
Nonductal: 570 (18.9)
Treatments, n (%):
Type of surgery:
Mastectomy: 1607 (53.5),
Lumpectomy: 1395 (46.5);
CTX: 1335 (44.5);
HT: 1117 (37.2);
RT: 1300 (43.3)
Lumpectomy vs.
Mastectomy
No CTX vs. CTX
Previous RT vs. No RT
HT vs. No HT
Sleep difﬁculty:
59.7% vs. 56.6%, p ¼ 0.14
Adjusted OR: 1.22, p ¼ 0.015
Sleep difﬁculty:
59.1% vs. 56.4%, p ¼ 0.15
Premenopausal women:
Adjusted OR: 1.29, p ¼ 0.16
Menopausal women: NS
Sleep difﬁculty:
59.8% vs. 56.4%, p ¼ 0.06
Sleep difﬁculty:
60.2% vs. 56.6%, p ¼ 0.06
Multivariate analysis including age,
marital status, ethnicity, education,
personal income, household wealth,
municipality size, children psychiatric
history, comorbidity, BMI, menopausal
status, alcohol/week, cigarettes/day,
physical activity, physical functioning,
depression and anxiety
e
e
Rand,
2011 [16]
Country: USA
Type of study:
Cross-sectional analysis
Aim: “To evaluate
the relationships among
measures of hot ﬂushes,
perceived hot
ﬂush interference,
sleep disturbance,
and (…) QL”
Study population:
BCA survivors due
to receive AI as initial
adjuvant HT or
following adjuvant
tamoxifen and
completed adjuvant
CTX if indicated
Sample size: n ¼ 395
Age (yr), Mean (SD): 59.3(8.7),
Range: 35-89
Cancer stage: Stage 0eStage III
Treatments: Time since ﬁrst
surgery for BCA, Mean (SD):
16.4 months (20.4)
Prior tamoxifen vs.
No prior tamoxifen
Sleep disturbance:
b ¼ 0.22, p < 0.05
Structured equation modelling,
including age at surgery, SSRI use,
alcohol use, CTX, ever smoked,
BMI, hot ﬂash severity and frequency,
perceived interference, sleep
disturbance, perceived health
status, anxiety symptoms,
depressive symptoms
Bardwell,
2008 [31]
Country: USA
Type of study:
Cross-sectional analysis
Aim: To assess the
“relative importance
of a wide range of
risk factors for
insomnia” in women
in history of BCA
Age (yr), Mean: 53,
Range: 28-74
Cancer stage, n (%): Stage I:
1033 (39.0), Stage II:
1488 (56.2),
Stage IIIA: 125 (4.7)
Time since diagnosis, n (%):
<1 yr: 615 (23.2), 1e1.9
yr: 836 (31.6),
CTX (with or
without RT) vs. No CTXg
RT (with or
without CTX) vs. No RTg
CTX vs. RTg
Tamoxifen (ever) vs.
No tamoxifen (never)h
Insomnia: 40.0% vs. 38.6%,
p ¼ 0.651a
Insomnia: 39.4% vs. 39.0%,
p ¼ 0.834a
Insomnia: 39.0% vs. 38.4%,
p ¼ 0.828a
Insomnia: 39.9% vs. 37.9%,
p ¼ 0.307a
e
e
e
e
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(continued )
1st author,
Year of
publication (REF)
Study description Subjects characteristics Association between breast cancer
treatments and sleep disturbances
Treatment comparison Main results Control of confounding
Study population:
Women 4 years
post-treatment for Stage I
(1 cm)eIIIA BCA
Sample size: n ¼ 2646
“Insomnia”: n ¼ 1039 vs.
“No insomnia”: n ¼ 1607
2e2.9 yr: 654 (24.7), 3e4
yr: 541 (20.4)
Treatments, n (%): Surgery þ
RT: 518 (19.6); Surgery þ
CTX: 720 (27.2); Surgery þ
CTX þ RT: 1113 (42.1);
Surgery only: 295 (11.1);
Tamoxifen: Current: 1589
(60.1), Former: 191 (7.2),
Never: 866 (32.7)
Palesh,
2008 [30]
Country: USA
Period of data collection:
Type of study: Cross-sectional
Aim: “ To determine
the relationship
between hypothalamic
pituitary axis
(HPA) dysregulation,
vagal functioning,
and sleep problems in women
with metastatic BCA”
Study population:
Women with
metastatic BCA or
recurrent BCA
Sample size: n ¼ 99
Age (yr), Mean (SD): 54.7
(9.6), Range: 36e80
Cancer stage: Metastatic
or recurrent BCA
Treatments, n (%):
CTX: 80 (86),
RT: 75 (81.5), HT: 61 (65.6)
CTX vs. No CTX
RT vs. No RT
HT vs. No HT
Total time in bed:
rho ¼ 0.29, p ¼ 0.006;
b ¼ 0.38, p ¼ 0.001f
Latency: rho ¼ 0.14,
p  0.05;
b ¼ 0.30, p ¼ 0.02
Sleep efﬁciency:
rho ¼ 0.12, p0.05
WASO: rho ¼ 0.04,
p  0.05
Mean number of wake episodes:
rho ¼ 0, p  0.05
Average wake episode period:
rho ¼ 0.09, p  0.05
Total time in bed:
rho ¼ 0.08, p  0.05
Latency: rho ¼ 0.21,
p < 0.05f
Sleep efﬁciency:
rho ¼ 0.14, p  0.05
WASO: rho ¼ 0.10, p  0.05
Mean number of wake episodes:
rho ¼ 0.13, p  0.05
Average wake episode period:
rho ¼ 0.09, p  0.05
Total time in bed: rho ¼ 0.16,
p0.05
Latency: rho ¼ 0.20, p  0.05
Sleep efﬁciency: rho ¼ 0.19,
p  0.05
WASO: rho ¼ 0.24, p ¼ 0.03f
Mean number of wake episodes:
rho ¼ 0.23, p ¼ 0.03
Average wake episode period:
rho ¼ 0.12, p  0.05
Hierarchical regression adjusted for CTX,
pain, depression
Hierarchical regression for CTX, RT
and perceived stress
e
e
e
e
e
e
e
e
e
e
e
e
e
e
e
e
Fortner,
2002 [32]
Country: USA
Period of data collection:
Type of study:
Age (yr), Mean (SD):
51.3 (11.7)
Treatments: Receiving
CTX or RT vs.
No current treatment
Sleep disturbance:
Mean (SD):1.52 (0.64) vs.
1.24 (0.58), p < 0.06 (NS)f
e
A
.R.Costa
et
al./
The
Breast
23
(2014)
697
e
709
706
Cross-sectional
Aim: To “describe sleep
in a heterogeneous
sample of breast cancer
patients (…) and
examined the relation
between sleep
disturbance and
health-related QL”
Study population: Breast
cancer patients
presenting to an outpatient
oncology clinic
(19 pre-cancer treatment,
29 receiving
cancer treatment, 23
post-cancer treatment)
Sample size: n ¼ 72
CTX or RT: 41% Sleep latency:
Mean (SD): 1.31 (1.04) vs.
0.93 (0.84), p < 0.10 (NS)
e
Stein,
2000 [33]
Country: USA
Type of study: Cross-sectional
analysis
Aim: “To (…) document
the prevalence
and severity of hot
ﬂashes (…) during
treatment for BCA; [to]
identify medical,
demographic, and
treatment correlates
of hot ﬂashes during
BCA treatment; and [to]
determine the impact of
the hot ﬂashes on (…) QL”
Study population:
Postmenopausal
women with BCA evaluated
during CTX or RT
Sample size: n ¼ 70
Age (yr), Range: 39-81
Cancer stage, n (%):
Stage I: 29 (41.4), Stage II:
34 (48.6), Stage III: 7(10.0)
Treatments, n (%):
Type of Surgery:
Mastectomy: 24 (34.3),
Lumpectomy: 43 (61.4),
Breast Biopsy: 3 (4.3);
CTX: 28 (40); RT: 42(60);
Tamoxifen: 6 (8.6)
CTX vs. RT Sleep Quality: b ¼ 0.11,
p  0.10
Multivariate analysis
including education
Berger,
1998 [34]
Country: USA
Type of study: Cohort
Aim: To describe
“patterns of fatigue
and of activity and rest and
the relationship between
these variables”
Study population:
Newly diagnosed
women with stage I
or II BCA during
the ﬁrst three adjuvant
Age (yr), Mean (SD):
49.5 (8.64), Range: 33e69
Cancer stage, n: Stage I: 32,
Stage II: 40
Lymph node status:
Positive: 33, Negative: 39
Treatments, n (%):
Type of Surgery: Breast
conservation: 34, Modiﬁed
radical mastectomy with
reconstruction: 10, Modiﬁed
radical mastectomy without
reconstruction: 28;
Doxorubicin vs.
Non-doxorubicin
Mesor:
Mean (SD): 101.87 (15.48)
vs. 113.73 (13.90), p ¼ 0.024
Amplitude:
Mean (SD):85.86 (19.39)
vs. 95.09 (13.90), p ¼ 0.125
Mesor plus amplitude:
Mean (SD): 183.18 (45.46)
vs. 209.66 (53.76),
p ¼ 0.002f
Awakenings at night:
Mean (SD): 21.77 (14.10)
e
e
e
e
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